Get started

Financials · SBFM

Sunshine Biopharma Inc. (SBFM) financials

For the twelve months ended Jun 30, 2026, Sunshine Biopharma Inc. reported $35.35M of revenue and -$5.83M of net income.

Revenue, TTM
$35.35M
Revenue growth, YoY
-2.7%
Net income, TTM
-$5.83M
Net margin
-16.5%
Free cash flow, TTM
-$5.37M
Cash
$13.75M
P/S
0.06
Market cap
$2.1M
Annual revenue$36.31M
FY2017FY2025
Annual net income-$5.98M
FY2016FY2025
Annual free cash flow-$5.51M
FY2016FY2025

SBFM revenue and earnings growth

SBFM revenueQ2 2026$9.26M

Quarter YoY
-1.6%
QoQ
+14.5%
FY YoY
+4.1%
5Y CAGR
+247.7%

SBFM revenue was $9.26M in fiscal Q2 2026 (ended Jun 30, 2026), down 1.6% from a year earlier and up 14.5% from the prior quarter. For the full fiscal 2025 it was $36.31M, up 4.1% from fiscal 2024. Compound annual growth was +247.7% over 5 years. It rose in each of the last 6 fiscal years. Fiscal 2025 is the highest of the 9 fiscal years on file.

SBFM net incomeQ2 2026-$1.56M

SBFM net income was -$1.56M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.77M a year earlier. For the full fiscal 2025 it was -$5.98M, compared with -$5.13M in fiscal 2024.

SBFM EPSQ2 2025-$0.82

SBFM diluted EPS was -$0.82 in fiscal Q2 2025 (ended Jun 30, 2025). For the full fiscal 2024 it was -$7.32.

SBFM free cash flowQ2 2026-$925.0K

SBFM free cash flow was -$925.0K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.43M a year earlier. For the full fiscal 2025 it was -$5.51M, compared with -$14.18M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$36.31M$34.87M$24.09M$4.35M$228.4K$71.4K$21.1K$0$0-
Cost of revenue$24.05M$24.20M$15.75M$2.65M$117.8K$25.8K$11.1K$0$0-
Gross profit$12.26M$10.67M$8.34M$1.70M$110.6K$45.6K$10.1K$0$0-
Research and development$604.3K$933.9K$1.86M$811.9K$672.2K$1.7K$15.2K$12.8K$0$32.8K
Selling, general and admin$18.48M$16.48M$13.12M$28.70M$2.55M$622.4K$651.7K$1.16M$857.2K$993.1K
Operating income-$6.23M-$5.81M-$4.79M-$27.00M-$2.44M-$576.9K-$641.6K-$1.16M-$857.2K-$993.1K
Interest expense$0$8.8K$137.3K$39.4K$328.8K$168.1K$115.9K$143.5K$104.8K$34.7K
Pre-tax income-$5.95M-$5.37M-$4.11M-$26.51M-$12.44M-----
Income tax$21.6K-$234.9K$395.2K$233.3K$0$0----
Net income-$5.98M-$5.13M-$4.51M-$26.74M-$12.44M-$2.78M-$1.66M-$2.16M-$1.04M-$3.50M
EPS, basic-$1.44-$7.32-$351.36-$1.76-$4.76-$2.73-$0.15-$0.71-$0.02-$0.01
EPS, diluted--$7.32-$351.36-$1.76-$4.76-----
Diluted shares-701,74912,82515.2M2.6M-----

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$9.12M$9.69M$16.29M$21.83M$2.05M$989.9K$40.5K$115.2K$107.5K$57.5K
Receivables$3.46M$3.87M$2.55M$1.91M$7.8K$1.9K$430$0$0-
Inventory$13.47M$11.28M$5.73M$3.29M$105.7K$23.8K$15.9K$0--
Current assets$26.85M$25.97M$24.89M$27.31M$2.20M$1.03M$65.7K$1.10M$117.2K$58.5K
Goodwill-$0$0$0$0-$665.7K$665.7K$0-
Total assets$30.08M$30.56M$27.35M$29.24M$2.20M$1.05M$98.1K$1.15M$257.5K$64.4K
Current liabilities$6.44M$6.31M$5.55M$6.93M$91.2K$1.05M$833.5K$912.5K$751.1K$274.1K
Total debt$0$0-$0$1.90M$949.0K-$419.7K$596.6K$69.9K
Total liabilities$7.04M$7.06M$6.14M$7.62M$1.99M$2.00M$833.5K$1.20M$830.8K$274.1K
Shareholders' equity$23.04M$23.50M$21.21M$21.63M$211.7K-$954.8K-$735.4K-$55.8K-$573.4K-$209.7K

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$5.33M-$12.52M-$8.78M-$5.25M-$1.83M-$657.3K-$495.8K-$512.8K-$543.5K-$314.2K
Capital expenditures$174.5K$1.66M$82.3K$194.0K$0$1.2K$860$18.9K$3.7K$3.4K
Free cash flow-$5.51M-$14.18M-$8.86M-$5.44M-$1.83M-$658.5K-$496.7K-$531.7K-$547.2K-$317.6K
Investing cash flow-$836.3K-$1.98M-$656.1K-$14.62M$0-$1.2K-$15.3K-$13.9K-$84.0K-$3.4K
Financing cash flow$4.75M$8.94M$3.43M$39.47M$2.90M$1.61M$442.3K$527.6K$670.7K$324.6K
Share repurchases$0$3.14M$541.1K-------
Stock-based compensation-----$271.9K$277.3K$755.2K$520.3K$499.4K
Depreciation and amortization$332.1K$223.5K$149.1K$25.2K$12.7K$14.1K$13.8K$49.4K$6.6K$60.7K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY4.1%44.7%454.4%1802.4%219.9%238.1%----
Gross margin33.8%30.6%34.6%39.0%48.4%63.8%47.7%---
Operating margin-17.2%-16.7%-19.9%-621.3%-1068.2%-807.8%-3037.9%---
Net margin-16.5%-14.7%-18.7%-615.4%-5444.4%-3898.7%-7860.9%---
Free cash flow margin-15.2%-40.7%-36.8%-125.2%-800.8%-922.1%-2351.5%---
Return on equity-25.9%-21.8%-21.2%-123.7%-5875.6%-----
Return on assets-19.9%-16.8%-16.5%-91.5%-564.6%-266.3%-1691.7%-188.1%-404.0%-5429.3%
Current ratio4.174.114.483.9424.070.980.081.210.160.21
Debt to equity0.000.00-0.008.98-----

Source: XBRL data Sunshine Biopharma Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

SBFM peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
SBFM$35.35M-2.7%-$5.83M-16.5%$2.1M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

SBFM FAQ

8 questions
  • What is SBFM revenue?
    Sunshine Biopharma Inc. (SBFM) reported $35.35M of revenue for the twelve months ended Jun 30, 2026. That is down 2.7% from the year before. Revenue for fiscal 2025 was $36.31M.
  • Is SBFM profitable?
    No. Sunshine Biopharma Inc. reported a net loss of $5.83M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does SBFM have?
    Sunshine Biopharma Inc. reported $13.75M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is SBFM revenue growing?
    Sunshine Biopharma Inc.'s revenue changed +4.1% in fiscal 2025, to $36.31M. Its compound annual growth rate was +247.7% over 5 years.
  • What is SBFM gross margin?
    Sunshine Biopharma Inc.'s gross profit was $10.71M on $35.35M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 30.3%.
  • What is SBFM free cash flow?
    Sunshine Biopharma Inc. generated -$5.37M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$5.35M less capital expenditures.
  • When did SBFM last report financial results?
    The latest statements here come from Sunshine Biopharma Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this SBFM financial data come from?
    Quantisnow builds these statements from the structured XBRL data Sunshine Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.